Since Allena Pharmaceuticals Inc. (NASDAQ:ALNA) and Prothena Corporation plc (NASDAQ:PRTA) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of both companies.
Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allena Pharmaceuticals Inc. N/A 0.00 32.72M -1.58 0.00 Prothena Corporation plc N/A 555.68 155.64M -4.63 0.00 In table 1 we can see Allena Pharmaceuticals Inc. and Prothena Corporation plc’s top-line revenue, earnings per share and valuation.
Table 2 has Allena Pharmaceuticals Inc. and Prothena Corporation plc’s return on assets, return on equity and net margins.
14.7 and 14.7 are the respective Current Ratio and a Quick Ratio of Allena Pharmaceuticals Inc. Its rival Prothena Corporation plc’s Current and Quick Ratios are 19.3 and 19.3 respectively. Prothena Corporation plc has a better chance of clearing its pay short and long-term debts than Allena Pharmaceuticals Inc.
Insider & Institutional Ownership
The shares of both Allena Pharmaceuticals Inc. and Prothena Corporation plc are owned by institutional investors at 88.5% and 0% respectively. 11.95% are Allena Pharmaceuticals Inc.’s share owned by insiders. On the other hand, insiders owned about 90.1% of Prothena Corporation plc’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Allena Pharmaceuticals Inc. -5.55% 11.6% -17.9% -34.44% -40.4% -12.03% Prothena Corporation plc -3.66% -11.14% -17.36% -17.48% -71.5% -69.14% For the past year Allena Pharmaceuticals Inc.’s stock price has smaller decline than Prothena Corporation plc.
On 4 of the 7 factors Allena Pharmaceuticals Inc. beats Prothena Corporation plc.
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The companyÂ’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in DÃºn Laoghaire, Ireland.
Click here to view original web page at Allena Pharmaceuticals Inc. (ALNA) and Prothena Corporation plc (NASDAQ:PRTA) Comparing side by side